Multiple Sclerosis: ABP 692 vs. Ocrevus

We are comparing a new treatment called ABP 692 with Ocrevus for people with relapsing-remitting multiple sclerosis. The goal is to see how they differ in effectiveness and safety.

>2 years 16-20 visits Confirmation phase (III)No Placebo Cost Reimbursement Investigational Medicines InjectionNeurology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Ocrevus

Ocrevus is a medicine used to treat multiple sclerosis, helping reduce relapses and slow progression of disability.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Ocrelizumab

Ocrelizumab is a substance used to treat multiple sclerosis by targeting specific immune cells to reduce inflammation and nerve damage.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Abp 692

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Noorderhart

Neurology

Overpelt, Belgium

Algemeen Ziekenhuis Delta

Neurology

Rumbeke, Belgium

Universitair Ziekenhuis Antwerpen

Neurology

Wilrijk, Belgium

Sponsor: Amgen Inc.

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.